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Abstract
Background: Endometrial cancer is the fourth most prominent cancer among all feminine cancers
in the Western world. Resveratrol, a natural anti-oxidant found in red wine emerging as a novel
anticancer agent, exerts antiproliferative and pro-apoptotic activity in various cancer cell types, but
its effect on uterine cancer cells is poorly understood. At the molecular level, resveratrol has been
reported to inhibit cyclooxygenase (COX) expression and/or activity; in endometrial cancer cells,
COX-2 is overexpressed and confers cellular resistance to apoptosis. The aim of the present study
was to determine if resveratrol could exert anti-proliferative and pro-apoptotic activity over
uterine cancer cells upon inhibition of COX-2 expression and/or activity. Six different human
uterine cancer cell lines were used as a model (HeLa, Hec-1A, KLE, RL95-2, Ishikawa and EN-
1078D).
Results and discussion: High-dose of resveratrol triggered apoptosis in five out of six uterine
cancer cell lines, as judged from Hoechst nuclear staining and effector caspase cleavage. In
accordance, uterine cancer cell proliferation was decreased. Resveratrol also reduced cellular
levels of the phosphorylated/active form of anti-apoptotic kinase AKT. Endogenous COX-2 protein
levels were decreased, concomitant with a decrease in production of COX metabolites PGE2 and
PGF2α, in each uterine cancer cell line expressing detectable levels of COX-1 and/or COX-2 in
presence of resveratrol. Although COX expression was identified as a target of resveratrol in
uterine cancer cells, inhibition of COX activity or exogenously added PGE2 did not modulate the
effect of resveratrol on cellular proliferation.
Conclusion: High-dose of resveratrol exerts tumoricidal activity over uterine cancer cells and
regulates COX expression. In these cells, resveratrol would not directly target COX activity, but
possibly other enzymes involved in prostaglandin synthesis that act downstream of the COXs.
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Background
Resveratrol (3,4',5-trihydroxy-trans-stilbène) is a natural
phytoalexin present in grape skins and consequently, in
red wines and grape juices [1,2]. When used at low con-
centrations resveratrol has cytoprotective activity, which is
mostly attributed to its antioxidant properties [3]. How-
ever, when administered at higher doses, resveratrol pos-
sesses anti-cancer activity by interfering with different
cellular events associated with initiation, promotion and
progression of multi-stage carcinogenesis [4]. The chemo-
preventive activity of resveratrol has notably been demon-
strated in breast [5] and prostate [6] cancers. The
anticancer potential of resveratrol in endometrial carci-
noma, however, remains unknown.
Endometrial carcinoma is the fourth type of cancer with
respect to incidence rates and is the leading type of gyne-
cological cancer in the Western world. In mutated-PTEN
endometrial tumors, which constitute around 50% of all
tumors [7], AKT is constitutively phosphorylated [8] and
its activity notably leads to up-regulation of COX-2 [8,9].
COX-2 up-regulation has also been found in other types
of cancers such as cervix [10], prostate [11] and breast
[12], where it has been shown to play a role in tumorigen-
esis [13-15]. In endometrial carcinoma cells, expression of
COX-2 notably confers resistance to apoptosis [8]. Similar
to COX-2, COX-1 is up-regulated in different carcinomas
[16,17] and plays a role in tumorigenesis [18,19]; COX-1
is also present in endometrial tumors [20]. COX-1 and
COX-2 are the rate-limiting enzymes involved in the bio-
synthesis of prostaglandins (PGs). PGE2, their major
metabolite, mediates its biological function through
interaction with the G protein-coupled receptors [21],
namely EP1, EP2, EP3 and EP4. The EP1 receptor activates
phospholipase C and the mobilization of the inositol tri-
phosphate pathway; the EP2 and EP4 receptors are cou-
pled to the adenylate cyclase and activate the cAMP/
protein kinase A pathway, and the EP3 receptor inhibits
adenylate cyclase and activates the phospholipase C [22].
The synthesis of PGE2 would be key elements in the
pathophysiology of different cancers [23,24]; notably,
PGE2 exerts immunosuppressive [25,26] as well as pro-
angiogenic [27,28] activities.
The malignant uterus thus constitutes a potential target of
resveratrol, given that resveratrol has been shown to
inhibit COX-2 transcription and activity [29,30], and that
COX-2 is overexpressed in a large proportion of endome-
trial tumor cells lines [8] and a majority of human
endometrial carcinoma specimens [20,31]. In light of our
previous findings that the presence of COX-2 promotes
the survival of endometrial tumor cells [8], we hypothe-
sized that resveratrol could exert tumoricidal activity over
uterine cancer cells upon inhibition of COX-2 expression
and/or activity. In addition, recent reports by Szewczuk
and colleagues suggest that resveratrol can also inhibit the
enzymatic activity of COX-1 [32-34], which is present in
many endometrial tumor tissues [20]; it is therefore pos-
sible that resveratrol would also modulate COX-1 expres-
sion and/or activity in uterine cancer cells. We have
undertaken the present study to determine how resvera-
trol influences survival/apoptosis, and COX expression
and activity in uterine cancer cells. Our results showed
that resveratrol can induce apoptosis in five of the six uter-
ine cancer cell lines studied, triggering effector caspase
cleavage and decreasing phospho-Akt levels. Concomitant
reduction in COX-2 levels and prostaglandins production
was observed.
Results
Resveratrol triggers apoptosis in uterine cancer cells
Resveratrol has been shown to trigger apoptosis in a few
tumor cell types [35,36], and we examined whether res-
veratrol could also exert pro-apoptotic activity in uterine
cancer cells. Hoescht staining revealed that a low dose of
10 μM resveratrol was sufficient to increase apoptosis in
HeLa, EN-1078D, HEC-1A and RL95-2 (Fig. 1A), whereas
a higher dose of 100 μM resveratrol was required to
increase significantly the apoptotic index of Ishikawa
cells. In accordance, Western blot analysis of caspase-3
cleavage showed that resveratrol increased the levels of the
active form of caspase-3 in the six cancer cell lines tested
(Fig. 1B). These results indicate that resveratrol can acti-
vate apoptotic pathways in uterine cancer cells.
Resveratrol interferes with AKT survival pathway in 
uterine cancer cells
Resveratrol has been reported to inhibit AKT activation
[37,38], and we have previously demonstrated that the
activity of AKT directly modulated survival/apoptosis in
uterine cancer cells [8]. We have thus determined whether
resveratrol interfered with AKT phosphorylation/activa-
tion in uterine cancer cell lines. Intracellular levels of
phosphorylated (active) AKT were not modified by resver-
atrol at 10 μM, but we found that a dose of 100 μM of res-
veratrol decreased the levels of phosphorylated AKT in the
three cell lines expressing constitutive levels of the kinase
(KLE, RL95-2 and Ishikawa), while it had no observable
effect on the other cell lines (Fig. 1C), indicating that res-
veratrol interferes with AKT activity in uterine cancer cells.
Resveratrol modifies the proliferating activity of uterine 
cancer cells
Resveratrol has been shown to exert antiproliferative
activity on particular tumor cell types [5,6,39], and we
have determined whether it could also modulate the
growth properties of uterine cancer cells. To this aim, MTT
assay was performed on uterine cancer cells that had been
treated with increasing concentrations of this natural
compound. We found that resveratrol indeed modifiedMolecular Cancer 2006, 5:45 http://www.molecular-cancer.com/content/5/1/45
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Effect of resveratrol (0 (control or Ctrl), 10 and 100 μM) on apoptosis induction in HeLa, HEC-1A, KLE, RL95-2, Ishikawa and  EN-1078D cell lines, after a period of 48 hours Figure 1
Effect of resveratrol (0 (control or Ctrl), 10 and 100 μM) on apoptosis induction in HeLa, HEC-1A, KLE, RL95-2, Ishikawa and 
EN-1078D cell lines, after a period of 48 hours. A) Hoescht nuclear staining was performed, and apoptotic cells were counted 
under a microscope. Results, presented as a percentage of apoptotic cells to the total cell count, are mean +/- SEM of three 
independent experiments. B) Cleavage/activation of caspases-3 was monitored by Western blot. GAPDH was used as a load-
ing control; results are mean +/- SEM of three independent experiments. C) The effect of resveratrol of the levels of pAKT 
was determined by western blot analysis. GAPDH was used as a loading control. Results are mean +/- SEM of at least two inde-
pendent experiments. *p < 0.05 compared to control cells (Ctrl).
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the proliferating activity of uterine cancer cells, and its
effect was biphasic: cellular proliferation was transiently
increased at low doses (3.125–12 μM), whereas higher
concentrations (50–100 μM) of resveratrol rather caused
time-dependent decrease of proliferating activity (Fig. 2).
These results indicate that resveratrol modifies the prolif-
erating activity of uterine cancer cells.
Resveratrol regulates COX expression in uterine cancer 
cells
It has been reported that resveratrol modifies COX levels
in varying cell types [30,40]. In order to determine the
effect of resveratrol on the expression of COX enzymes in
uterine cancer cells, we have treated these cells with a low
(10 μM) and a high (100 μM) dose of resveratrol, and sub-
sequently measured COX levels using western blot. We
found that COX-1 was regulated by resveratrol in only one
of the six cell lines tested: in Ishikawa cells, resveratrol
caused a dose-dependent increase in COX-1 expression
(Fig. 3A). In contrast, resveratrol had various effects on
COX-2 levels, depending on the dose and the cell line that
were used. In cells expressing high constitutive COX-2 lev-
els (Hela, RL95-2 and Ishikawa), 10 μM resveratrol further
increased these levels; however, a dose of 100 μM resvera-
trol rather decreased COX-2 levels in all cell lines tested
except for Hela cells (Fig. 3B). We also evaluated whether
resveratrol had an effect on the production of prostaglan-
dins by uterine cancer cells. First, our results showed that
these cells constitutively produce varying levels of PGE2,
a major metabolite of COX enzymes, which correlate well
with endogenous COX levels (Fig. 3A–C). Then, resvera-
trol had no effect on the production of PGE2 by KLE and
EN-1078D cell lines, which do not express detectable lev-
els of any of the COX enzymes (Fig 3C); noteworthy, in
the four cells lines containing endogenous levels of COX-
1 and/or COX-2 enzymes (Hela, Hec-1A, RL95-2 and
Ishikawa), resveratrol decreased the production of PGE2
(Fig. 3C), irrespective of its effect on COX levels which
varied depending on the dose used (Fig. 3A–B). Moreover,
the levels of PGF2α, another metabolite of COX activity,
were also decreased by resveratrol (data not shown). Col-
lectively these results indicate that in addition to interfer-
ing with COX expression, resveratrol inhibits the
production of prostaglandins by uterine cancer cells.
COX activity might not be involved in resveratrol-induced 
cell proliferation
At low dose resveratrol increases the proliferation (Fig. 2),
and upregulates COX levels (Fig. 3B) in multiple uterine
cancer cell lines. Since increased COX-2 levels has been
shown to promote survival of uterine cancer cells [8], we
hypothesized that elevated COX enzymes levels could
promote the proliferating activity of these cells and could
be involved in the positive effect of low-dose resveratrol
on cellular proliferation. We found that indomethacin,
which inhibits the activity of both COX-1 and COX-2
enzymes, decreased basal proliferation of Hela and KLE
cell lines (Fig. 4); we also observed that NS-398, a selective
in inhibitor of COX-2 activity, decreased cellular prolifer-
ation of RL95-2, Ishikawa and EN-1078D (data not
shown), suggesting that COX enzymes are involved in
basal proliferating activity of uterine cancer cells. In a
combined treatment however, indomethacin did not
block the positive action of low-dose of resveratrol on cel-
lular proliferation (Fig. 4). Similarly, NS-398 could not
interfere with the effect of low-dose of resveratrol on cel-
lular proliferation (data not shown), indicating that the
increase of cellular proliferation following exposure to
low-dose resveratrol does not result from increased COX
activity. Noteworthy, indomethacin and NS-398 did not
mediate the anti-proliferative effect of high-dose resvera-
trol on uterine cancer cell proliferation (data not shown),
suggesting that resveratrol does not decrease uterine can-
cer cell proliferation by inhibiting COX activity.
PGE2 does not interfere with resveratrol antiproliferative 
activity
Since high-dose of resveratrol decreases PGE2 production
in uterine cancer cells (Fig. 3C), concomitant with a
decrease in cellular proliferation (Fig. 2), we hypothesized
that PGE2 could promote cellular proliferation and coun-
teract the anti-proliferative effect of high resveratrol dose.
First we assessed the presence of PGE2 receptors on the six
uterine cancer cells lines, and observed that more than
one EP receptor were expressed by each cell line (Fig. 5A).
EP1 was more abundant in HEC-1A cells, while EP2 was
expressed at higher levels in HeLa cells; EP3 mRNA was
found to be elevated in Ishikawa cell line compared with
the five other cancer cell lines tested and RL95-2 expressed
the highest levels of EP4 (Fig. 5A). We next chose as a
model Ishikawa and EN-1078D; Ishikawa cells constitu-
tively express COX enzymes, the levels of which are mod-
ulated by resveratrol, and conversely EN-1078D cells
express no detectable levels of COX, even in the presence
of resveratrol (Fig. 3A–B). The two cell lines were incu-
bated with increasing concentrations of PGE2, alone or in
combination with resveratrol (10 and 100 μM). We found
that PGE2 alone did not promote cellular proliferation in
these two cell lines (Fig. 5B–C); in addition, exogenous
PGE2 was not able to counteract the effect of resveratrol
on the proliferation of Ishikawa and EN-1078D cell lines
(Fig. 5B–C).
Discussion
Resveratrol, a phytoestrogen found in food products such
as grape and wine, produces various physiological effects.
At low concentrations normally occurring in food, resver-
atrol has been shown to exert neuroprotective effects [41],
as well as beneficial effects on the cardiovascular system
[42,43]. These effects are mostly attributed to its anti-oxi-Molecular Cancer 2006, 5:45 http://www.molecular-cancer.com/content/5/1/45
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The effect of resveratrol (0 (control or Ctrl), 3.125, 6.25, 12, 25, 50 and 100 μM) on cellular proliferation in HeLa (■), HEC- 1A (▲), RL95-2 (), Ishikawa (●), KLE (❍) and EN-1078D () cells for a period of A) 24 hours, B) 48 hours and C) 72 hours  was determined by MTT proliferation assay Figure 2
The effect of resveratrol (0 (control or Ctrl), 3.125, 6.25, 12, 25, 50 and 100 μM) on cellular proliferation in HeLa (■), HEC-
1A (▲), RL95-2 (), Ishikawa (●), KLE (❍) and EN-1078D () cells for a period of A) 24 hours, B) 48 hours and C) 72 hours 
was determined by MTT proliferation assay. Results, which are presented as a percentage of proliferation of treated cells com-
pared to control (untreated) cells, are mean +/- SEM of three independent experiments, each performed in duplicates.
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The effect of resveratrol of the levels of A) COX-1 and B) COX-2 was determined by western blot analysis Figure 3
The effect of resveratrol of the levels of A) COX-1 and B) COX-2 was determined by western blot analysis. GAPDH was 
used as a loading control. Results are mean +/- SEM of at least two independent experiments. *p < 0.05 compared to control. 
C) The effect of a 48h-treatment with resveratrol (0, 10 and 100 μM) on PGE2 production by HeLa, HEC-1A, KLE, RL95-2, 
Ishikawa and EN-1078D cell lines was determined using EIA assay. Data represent the mean ± SEM of 4 independent experi-
ments. *p < 0.05 compared to control (Ctrl).
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Effect of resveratrol (0, 3.125, 6.25, 12, 25, 50 and 100 μM), in the presence or absence of 5 μM indomethacin for a period of  48 hours, on cellular proliferation in A) HeLa, B) HEC-1A, C) KLE, D) RL95-2, E) Ishikawa and F) EN-1078D cells as deter- mined by the MTT proliferation assay Figure 4
Effect of resveratrol (0, 3.125, 6.25, 12, 25, 50 and 100 μM), in the presence or absence of 5 μM indomethacin for a period of 
48 hours, on cellular proliferation in A) HeLa, B) HEC-1A, C) KLE, D) RL95-2, E) Ishikawa and F) EN-1078D cells as deter-
mined by the MTT proliferation assay. Data represent the mean ± SEM of 6 independent experiments.
A) B)
C)
E)
D)
F)
036 1 3 2 5
0
25
50
75
100
125
150
Hec-1A
Resveratrol
R + Indomethacin
Resveratrol (μM)
P
r
o
l
i
f
e
r
a
t
i
o
n
 
(
%
 
c
o
n
t
r
o
l
)
036 1 3 2 5
0
25
50
75
100
125
150
Hela
Resveratrol
R + Indomethacin
Resveratrol (μM)
P
r
o
l
i
f
e
r
a
t
i
o
n
 
(
%
 
c
o
n
t
r
o
l
)
036 1 3 2 5
0
25
50
75
100
125
150
KLE
Resveratrol
R + Indomethacin
Resveratrol (μM)
P
r
o
l
i
f
e
r
a
t
i
o
n
 
(
%
 
c
o
n
t
r
o
l
)
036 1 3 2 5
0
25
50
75
100
125
150
RL95-2
Resveratrol
R + Indomethacin
Resveratrol (μM)
P
r
o
l
i
f
e
r
a
t
i
o
n
 
(
%
 
c
o
n
t
r
o
l
)
036 1 3 2 5
0
25
50
75
100
125
150
Ishikawa
Resveratrol
R + Indomethacin
Resveratrol (μM)
P
r
o
l
i
f
e
r
a
t
i
o
n
 
(
%
 
c
o
n
t
r
o
l
)
036 1 3 2 5
0
25
50
75
100
125
150
EN-1078D
Resveratrol
R + Indomethacin
Resveratrol (μM)
P
r
o
l
i
f
e
r
a
t
i
o
n
 
(
%
 
c
o
n
t
r
o
l
)
A) B)
C)
E)
D)
F)
036 1 3 2 5
0
25
50
75
100
125
150
Hec-1A
Resveratrol
R + Indomethacin
Resveratrol (μM)
P
r
o
l
i
f
e
r
a
t
i
o
n
 
(
%
 
c
o
n
t
r
o
l
)
036 1 3 2 5
0
25
50
75
100
125
150
Hela
Resveratrol
R + Indomethacin
Resveratrol (μM)
P
r
o
l
i
f
e
r
a
t
i
o
n
 
(
%
 
c
o
n
t
r
o
l
)
036 1 3 2 5
0
25
50
75
100
125
150
KLE
Resveratrol
R + Indomethacin
Resveratrol (μM)
P
r
o
l
i
f
e
r
a
t
i
o
n
 
(
%
 
c
o
n
t
r
o
l
)
036 1 3 2 5
0
25
50
75
100
125
150
RL95-2
Resveratrol
R + Indomethacin
Resveratrol (μM)
P
r
o
l
i
f
e
r
a
t
i
o
n
 
(
%
 
c
o
n
t
r
o
l
)
036 1 3 2 5
0
25
50
75
100
125
150
Ishikawa
Resveratrol
R + Indomethacin
Resveratrol (μM)
P
r
o
l
i
f
e
r
a
t
i
o
n
 
(
%
 
c
o
n
t
r
o
l
)
036 1 3 2 5
0
25
50
75
100
125
150
EN-1078D
Resveratrol
R + Indomethacin
Resveratrol (μM)
P
r
o
l
i
f
e
r
a
t
i
o
n
 
(
%
 
c
o
n
t
r
o
l
)Molecular Cancer 2006, 5:45 http://www.molecular-cancer.com/content/5/1/45
Page 8 of 13
(page number not for citation purposes)
A) The levels of EP1 to EP4 receptors mRNA were determined in HeLa, HEC-1A, KLE, RL95-2, Ishikawa and EN-1078D cell  lines by quantitative real-time PCR Figure 5
A) The levels of EP1 to EP4 receptors mRNA were determined in HeLa, HEC-1A, KLE, RL95-2, Ishikawa and EN-1078D cell 
lines by quantitative real-time PCR. GAPDH was used as control to correct for loading. Data represent mean ± SEM of 3 inde-
pendent experiments. B) The effect of PGE2 (0, 10-9, 10-8, 10-7, 10-6, 10-5 and 10-4 M), in the presence or absence of 10 or 100 
μM resveratrol, was evaluated on cellular proliferation in B) Ishikawa and C) EN-1078D cells, for a period of 48 hours, using 
the MTT proliferation assay. Data represent the mean ± SEM of 6 independent experiments. Ctrl: untreated control.
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dant properties. More recently, resveratrol has been evalu-
ated for its health benefits in other medical areas, such as
oncology; resveratrol indeed possesses anticancer activity
when administered at higher, non-physiological doses. In
these conditions, resveratrol inhibits the proliferation and
induces apoptotic cell death in multiple cancers cell types
in vitro [6,44,45]; moreover, in animal models of cancer,
resveratrol has been shown to inhibit angiogenesis and
delay tumor growth [46], to impede carcinogenesis [4,47],
and to reduce experimental metastasis [48].
The malignant uterus constitutes a potential target for res-
veratrol. First, COX-2 is overexpressed in a large propor-
tion of endometrial tumors [8], and resveratrol has been
shown to inhibit COX expression and activity in a variety
of cell types [32,49]. Second, resveratrol has the capacity
to bind to the estrogen receptors α and β [50], and ER-α is
notably present and activated in the normal and neoplas-
tic endometrium [51]. Nonetheless, the effects of resvera-
trol on uterine cancer cells remain largely unknown. We
have examined the effect of resveratrol on survival/apop-
tosis of uterine cancer cells, in relation to its effects on
COX expression and activity. To this aim, we have used
five cancer lines of the human endometrium (Hec-1A,
KLE, RL95-2, Ishikawa and EN-1078D) and one cancer
line of the human uterine cervix (HeLa).
In the course of these experiments we have observed that
even though high doses (50–100 μM) of resveratrol
induce apoptosis in uterine cancer cells, at low doses (up
to 25 μM) resveratrol rather transiently increases prolifer-
ation in several uterine cancer cell lines. This indicates that
resveratrol activates, in a dose-dependent manner, distinct
cellular mechanisms in these cells. Our results showed
that even though low doses of resveratrol upregulate the
levels of COX-1 and/or COX-2 enzymes in uterine cancer
cells, COX activity is not involved in the increase of cellu-
lar proliferation caused by resveratrol. We have previously
demonstrated that Akt kinase was a central element in the
survival of uterine cancer cells when exposed to pro-apop-
totic agents [52], and it has been reported that resveratrol
at concentrations close to 10 μM could increase PI3-K
activity and the levels of phosphorylated/active Akt in
MCF-7 breast cancer cells [37]. We have found, however,
that the levels of phosphorylated Akt were not increased
in uterine cancer cells following exposure to low doses of
resveratrol, which suggests that resveratrol does not
increase the proliferation of uterine cancer cells through
Akt regulation. Resveratrol can act as an estrogen agonist
or antagonist, depending on the estrogen response ele-
ment sequence that is present and whether the phytoes-
trogen binds ERα or ERβ [50]; cells that only express ERβ
or that express higher levels of ERα compared to ERβ
would be more sensitive to the estrogen agonist activity of
resveratrol [50]. Among the six uterus cancer cell lines that
have been tested in the present study, Hela presents the
highest ratio ERβ to ERα, while EN-1078D (the only cell
line expressing ERα in our experimental conditions) has
the lowest expression [53]. We previously showed that
proliferation of uterine cancer cell lines was increased in
response to estrogen [53]. Thus, if resveratrol exerts estro-
gen agonist effect on ERβ uterine cancer cell lines, it
should stimulate proliferation in Hela but not in EN-
1078D. Our results showed the opposite, and this sug-
gests that low-dose induction of proliferation by resvera-
trol is not mediated through the ER pathway.
It had already been reported that resveratrol could
decrease the proliferation of Ishikawa cell line [54]. We
have obtained similar results with this cell line; in addi-
tion, we demonstrate that high-dose resveratrol induces a
diminution of cellular proliferation in five other uterus
cancer cell lines. Resveratrol also caused a rise in the apop-
totic cell death in all uterine cancer cells studied, except in
KLE cell line albeit there was an increase in cleaved cas-
pase-3 levels. In this regard, we have measured high levels
of XIAP, an endogenous inhibitor of effector caspases
such as caspase-3, in KLE cells (data not shown); this
could explain why the increase in cleaved caspase-3 levels
is not accompanied by an increase in apoptotic index.
Noteworthy, this cell line is also resistant to the cytotoxic
effects of various chemotherapeutic agents [52]. We have
also shown that in all uterus cancer cell lines containing
endogenous levels of the phosphorylated/active form of
AKT kinase (pAKT), high-dose resveratrol decreased pAKT
levels, concomitant with an increase in cleaved caspase-3
levels. Others had also reported that resveratrol can inter-
fere with PI3-kinase activity and Akt phosphorylation
[37,55,56] in cancer cells. These results are in agreement
with our previous findings that the activity of the PI3-K/
Akt pathway is involved in the survival of uterine cancer
cells [8].
We show that resveratrol has a dual effect on COX expres-
sion and prostaglandin production in uterine cancer cells.
Similar to other cell types, where resveratrol up- or down-
regulates COX levels [30,40,49,57,58], we demonstrate
that in uterine cancer cells resveratrol alters COX-2 expres-
sion, in a cell- and dose-specific manner. Szewczuk and
coworkers have shown that resveratrol can act on COX-1
enzymatic activity [32]; in agreement, we demonstrate
that resveratrol inhibits the production of PGE2  and
PGF2α in all cell lines expressing COX-1 (HeLa, HEC-1A
or Ishikawa). However, resveratrol also induced a diminu-
tion in the production of PGE2 and PGF2α in RL95-2 cells,
which express COX-2 but not COX-1. This leads us to
believe that resveratrol can act on a target other than the
COX-1 protein; in this regard, another study proposed an
effect of resveratrol on both the transcriptional activity of
COX-2 gene and COX-2 activity in breast cancer [49].Molecular Cancer 2006, 5:45 http://www.molecular-cancer.com/content/5/1/45
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Accordingly, all uterine cancer cell lines expressing COX-
2 (HeLa, RL95-2 and Ishikawa) have seen their PGE2 and
PGF2α levels decreased following a treatment with high
dose resveratrol, which also decreased COX-2 levels. It
should be noted, however, that even if resveratrol
increased COX-1 or COX-2 levels, which occurred when
the cells were exposed to low doses of resveratrol, PGE2
and PGF2α production were decreased. This suggests that
in addition to regulating the expression of COX-2, resver-
atrol might block the activity of enzymes involved in pros-
taglandin synthesis, possibly COX enzymes themselves
but also downstream prostaglandin synthases. We have
used pharmacological inhibitors to examine whether res-
veratrol directly targets COX activity. Our results have
showed that the activity of COX enzymes was involved in
basal proliferating activity of multiple uterine cancer cells
lines; others had reported similar results with pancreatic
cancer cells, which also produce endogenous levels of
COXs [59]. It appeared, however, that increase of cellular
proliferation following exposure to low-dose resveratrol
was not blocked by COX inhibitors indomethacin and
NS-398; in addition, indomethacin and NS-398 did not
modulate the anti-proliferative effect of high-dose of res-
veratrol (data not shown), suggesting that resveratrol does
not influence cellular proliferation by modulating COX
activity in uterine cancer cells. Moreover, the cell line EN-
1078D, which does not express detectable levels of COX
enzymes, was sensitive to the pro-apoptotic effects of
high-dose resveratrol. Taken together, these results suggest
that resveratrol does not directly target COX activity but
rather, downstream components involved in prostaglan-
din synthesis such as PGE and PGF synthases.
Bhat and coworkers have reported that resveratrol down-
regulates ER-α in Ishikawa cell line [60]. In most uterine
cancer cell lines ER-α is not likely to be targeted by resver-
atrol however, since it is rarely constitutively expressed
(data not shown). Others have reported that resveratrol
antagonizes ER-β at high doses [61]; blockade of ER-β
could very well occur in uterine cancer cells which all
express endogenous levels of this receptor (data not
shown). Noteworthy, in MCF-7 breast and Ishikawa
endometrial cancer cell lines, the anti-proliferative effect
of resveratrol was shown to be ER-independent [61,62]. It
may also be the case for the other uterine cancer cells stud-
ied.
It has been reported that resveratrol can interfere with PI3-
kinase activity [37]. In uterine cancer cells, the expression
of COX-2 is regulated by the activity of the PI3-K/Akt
pathway [8,9], and since resveratrol regulates COX-2
expression and the extent of phosphorylation of AKT in
cells expressing constitutive phospho-AKT levels, it is pos-
sible that PI3-K activity is targeted by resveratrol in these
cells. Although specific PI3-K inhibitor LY294002 inhibits
the growth of uterine cancer cells [8], preliminary experi-
ments indicate that LY294002 does not block the increase
of cellular proliferation triggered by low doses of resvera-
trol (data not shown), suggesting that PI3-K/AKT pathway
is not influenced by resveratrol, at least at low doses. This
does not rule out the possibility, however, that high-dose
resveratrol inhibits the activity of PI3-K, which could
explain the observed decrease in pAKT levels.
Conclusion
In conclusion, resveratrol can inhibit cell growth and trig-
ger apoptotic cell death in uterine cancer cells expressing
COX-1 and/or COX-2, in association with a decrease in
COX-2 expression and inhibition of prostaglandin pro-
duction. Noteworthy, resveratrol can also trigger apopto-
sis in uterine cancer cells which do not express detectable
levels of COX-1 and COX-2, confirming that resveratrol
can target other enzymes than COXs. This study on uter-
ine cancer adds to a growing body of evidence identifying
resveratrol as a promising anti-cancer agent.
Methods
Reagents
Resveratrol, Indomethacin, MTT (3-(4,5-dimethyl-thia-
zolyl-2)-2,5-diphephenyltetrazolium bromide) and
Hoechst 33258 were obtained from Sigma (St. Louis,
MO). Prostaglandin E2  was obtained from Cayman
Chemical (Ann Harbor, MI). DMEM-F12, Mc Coy's PCR
primers, FBS and BGS sera were purchased from Invitro-
gen (Burlington, ON). Cleaved caspase-3 antibodies were
obtained from New England Biolabs (Mississauga, ON)
and anti-human COX-1 and COX-2 GAPDH were
obtained from Cedarlane Laboratories (Hornby, ON).
Secondary horse radish peroxidase (HRP)-conjugated
anti-rabbit antibody and secondary horse radish peroxi-
dase (HRP)-conjugated anti-mouse antibody were pur-
chased from BioRad (Mississauga, ON).
MTT proliferation assay
Cells were plated at a density of 2 × 104 cells/well in 96-
well plates 24 hours before the assay. Cells were cultured
for 24, 48 and 72 hours in the presence of different con-
centrations of Resveratrol (0; 3.125; 6.25; 12.5; 25; 50 and
100 μM in 0,1 % DMSO). At the end of the culture period,
10 μl of MTT (5 mg/ml) was added to each well. After 3.5
hours of incubation with MTT, 100 μl of solubilization
solution was added (10% SDS in 0.01 M HCl) and the
microplate was incubated overnight (37°C, 5% CO2). The
OD was read with Microplate Manager (ELISA) at 550 nm.
MTT was also performed with Resveratrol (0; 3.125; 6.25;
12.5; 25; 50 and 100 μM in 0,1 % DMSO) in the presence
or absence of 5 μM (0,05% DMSO) indomethacin (COX
inhibitor), or 5 μM PGE2 (0, 10-9, 10-8, 10-7, 10-6, 10-5 and
10-4 M in 0,1% DMSO).Molecular Cancer 2006, 5:45 http://www.molecular-cancer.com/content/5/1/45
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Resveratrol treatment
HeLa, HEC-1A, KLE, RL95-2, Ishikawa and EN-1078D
cells were plated at a density of 1 × 106 cells/dish (100 mm
× 20 mm) 24 hours before treatment. Cells were treated
for 48 hours with resveratrol (0,10 and 100 μM).
Protein extraction and Western analysis
Cells (both floating and attached) were trypsinized, lysed
in lysis buffer (PBS 1X pH 7.4; 1% Nonidet P-40; 0.5%
Sodium deoxycholate; 0.1% SDS; Protease Inhibitor
Cocktail Tablets (Roche)), frozen at -20°C and thawed
three times, and centrifuged (13000 × g, 20 min at 4°C)
to remove insoluble material. Supernatant was recovered
and stored at -20°C pending analysis. Protein content was
determined with the Bio-Rad DC Protein Assay. Protein
extracts (50 μg) were heated (95°C, 3 min), resolved by
10% SDS-Polyacrylamide gel electrophoresis (PAGE) and
electro-transferred to nitrocellulose membranes (15 V, 30
min) using a semi-dry transfer (Bio-Rad, Mississauga,
ON). Membranes were then blocked (1 hour, RT) with
PBS containing 5% milk powder, then incubated with
anti-COX-1 (1:2 500), anti-COX-2 (1:2 000), anti-CDC47
(1:16 000), anti-cleaved caspase-3 (1:1 500) or anti-
GAPDH (1:50 000) antibody (overnight, 4°C), and sub-
sequently with Horse radish peroxidase (HRP)-conju-
gated anti-rabbit secondary antibody (1:3 000; RT, 45
min) for the anti-cleaved caspase-3 antibody or with HRP-
conjugated anti-Mouse secondary antibody (1:3 000, RT,
45 min) for the anti-COX-1, anti-COX-2 and anti-CDC47
and HRP-conjugated anti-Mouse secondary antibody
(1:60 000, RT, 45 min) for anti-GAPDH antibody. Perox-
idase activity was visualized with the WestSuper Femto
(Pierce), according to the manufacturer's instructions.
Hoechst staining
Following treatment, both floating and attached cells were
resuspended in PBS containing Hoechst 33258 for 24
hours and stored at 4°C. Hoechst nuclear staining was
viewed and photographed using a Olympus BX60 fluores-
cence microscope and a Coolsnap-Pro CF digital Camera
(Carsen Group, ON). Cells with typical apoptotic nuclear
morphology (nuclear shrinkage, condensation) were
identified and counted, using randomly selected fields on
numbered photographic slides, of which the "counter"
was not aware of the treatment, so as to avoid experimen-
tal bias. A minimum of 200 cells per treatment group were
counted in each experiment and results are presented as a
percentage of apoptotic cells.
Quantitative real-time RT-PCR analysis
In order to measure the abundance of COX-1, COX-2,
EP1, EP2, EP3 and EP4 mRNA, primers were chosen as
described below and tested with different primer concen-
trations and different cycles to avoid mRNA amplification
near plateau and saturation. Total RNA (0.2 μg/μl) was
used for preparation of first strand cDNA by reverse tran-
scriptase (RT). The RNA samples were incubated (65°C,
10 min) with 2 μl oligo dT (deoxythymidine) primers in
a final volume of 10 μl. Samples were then incubated
(37°C, 60 min) in 20 μl of a reaction buffer (1X) contain-
ing dithiothreitol (DTT; 100 mM), deoxynucleotide tri-
phosphates (dNTPs; 5 mM) and Muloney murine
leukemia virus reverse transcriptase (MMLV-RT; 10 U).
After cDNA synthesis, the reaction volumes were brought
up to 60 μl with autoclaved water. A negative control was
also included, using the same reaction mixture but with-
out RNA to ensure absence of any contaminating genomic
DNA in the RNA template.
Human COX-1 mRNA was amplified using sense primer
5'-GCAACTGCTTCTTCCCTTTG-3' and antisense primer
5'GGAGTTTGTCAATGCCACCT-3' and human COX-2
mRNA, was amplified using 5'-TGCTTGTCT-
GGACAACTGC-3' (sense) and 5'-TGAGCATCTACGGTTT-
GCTG-3' (antisense). For human EP1 mRNA, primers
sequences were 5'-TTGTCGGTATCATGGTGGTG-3' (sens)
and 5'-ATGTACACCCAAGGGTCCAG-3' (anti-sens),
human EP2 mRNA, primers sequences were 5'-TGCTTCT-
CATGGTCTCGGTG-3' (sens) and 3'-GTGAAAGGCAAG-
GAGCAGAC-3' (anti-sens), human EP3 mRNA, primers
sequences were 5'CAACCTTTTCTTCGCCTCTG-3' (sens)
and 5'-TTTCTGCTTCTCCGTGTGTG-3' (anti-sens) and
human EP4 mRNA, primers sequences were 5'-GACCT-
GTTGGGCACTTTGTT-3' (sens) and 5'-TGGACGCATA-
GACTGCAAAG-3' (anti-sens). Each reaction mixture
(final volume, 20 μl) contained RT template or negative
control (2 μl), primers (10 μM) and Quantitect
SYBRGreen Master Mix (10 μl). Each PCR reaction was
inserted in a LightCycler capillary. The quantitative PCR
cycling conditions (55 cycles) chosen were (1) 15s at
94°C; (2) 20s at 65°C (COX-1), 63°C (COX-2), 59°C
(EP1), 60°C(EP2), 60°C (EP3) and 60°C (EP4); and (3)
11 sec (COX-1), 14 sec (COX-2), 10 sec (EP1), 12 sec
(EP2), 15 sec (EP3) and 13 sec (EP4) at 72°C. A melting
curve was generated for each reaction and the conditions
were (1) 95°C, (2) 30 sec at the annealing temperature,
and (3) temperature up to 95°C (0.2°C/sec). Finally, the
cDNA concentration of each reaction was determined
quantitatively using a standard curve. GAPDH was used as
the control reaction.
PGE2 enzyme immunoassay
The procedure for PGE2 EIA kit (Cayman) described by the
manufacturer was followed. Briefly, a 50-μl aliquot from
culture medium obtained during experimentation was
used for PGE2 determination in a 96-well plate coated
with goat anti-rabbit secondary antibody. A volume of 50
μl of PGE2 tracer and 50 μl of the PGE2 antibody were
added to each sample and the plates were incubated over-
night at 4°C. Wells were washed with 10 mM phosphateMolecular Cancer 2006, 5:45 http://www.molecular-cancer.com/content/5/1/45
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buffer (pH 7.4) containing Tween 20 (0,05%) at pH 7.4 ;
200 μl of Ellman's reagent (69 mM acetylthiocholine and
54 mM 5,5'-dithio-bis [2-nitrobenzoic acid] in 10 mM
phosphate buffer, pH 7.4) was added to each well, and
samples were incubated in the dark at room temperature.
This allows the bound enzyme tracer to react with Ell-
man's reagent to yield a yellow solution that can be meas-
ured photometrically with a microplate reader at 410 nm.
A standard curve was developed simultaneously with
standards ranging from 50 to 1000 pg/ml PGE2. The pres-
ence of PGE2 was undetectable in the culture media in the
absence of cells.
Statistical analysis
All experiments were repeated at least six times. Data were
subjected to one-way ANOVA or student t test (PRISM
software version 4.0; GraphPad, San Diego, CA). Differ-
ences between experimental groups were determined by
the Tukey's test.
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